117 related articles for article (PubMed ID: 38467634)
21. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen.
Sahai V; Kumar K; Knab LM; Chow CR; Raza SS; Bentrem DJ; Ebine K; Munshi HG
Mol Cancer Ther; 2014 Jul; 13(7):1907-17. PubMed ID: 24807963
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Benoit E; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Jul; 23(34):5834-42. PubMed ID: 15208677
[TBL] [Abstract][Full Text] [Related]
23. CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma.
Duxbury MS; Ito H; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 May; 317(3):837-43. PubMed ID: 15081416
[TBL] [Abstract][Full Text] [Related]
24. A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.
Cazes A; Betancourt O; Esparza E; Mose ES; Jaquish D; Wong E; Wascher AA; Tiriac H; Gymnopoulos M; Lowy AM
Clin Cancer Res; 2021 Apr; 27(7):2100-2110. PubMed ID: 33451980
[TBL] [Abstract][Full Text] [Related]
25. Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer.
Duxbury MS; Matros E; Ito H; Zinner MJ; Ashley SW; Whang EE
Ann Surg; 2004 Oct; 240(4):667-74; discussion 675-6. PubMed ID: 15383794
[TBL] [Abstract][Full Text] [Related]
26. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
27. Preclinical models of pancreatic ductal adenocarcinoma.
Krempley BD; Yu KH
Chin Clin Oncol; 2017 Jun; 6(3):25. PubMed ID: 28705002
[TBL] [Abstract][Full Text] [Related]
28. Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system.
Schuth S; Le Blanc S; Krieger TG; Jabs J; Schenk M; Giese NA; Büchler MW; Eils R; Conrad C; Strobel O
J Exp Clin Cancer Res; 2022 Oct; 41(1):312. PubMed ID: 36273171
[TBL] [Abstract][Full Text] [Related]
29. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
[TBL] [Abstract][Full Text] [Related]
30. Pathophysiological role of microRNA-29 in pancreatic cancer stroma.
Kwon JJ; Nabinger SC; Vega Z; Sahu SS; Alluri RK; Abdul-Sater Z; Yu Z; Gore J; Nalepa G; Saxena R; Korc M; Kota J
Sci Rep; 2015 Jun; 5():11450. PubMed ID: 26095125
[TBL] [Abstract][Full Text] [Related]
31. Modeling pancreatic cancer in mice for experimental therapeutics.
Mallya K; Gautam SK; Aithal A; Batra SK; Jain M
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847
[TBL] [Abstract][Full Text] [Related]
32. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions.
Duxbury MS; Matros E; Clancy T; Bailey G; Doff M; Zinner MJ; Ashley SW; Maitra A; Redston M; Whang EE
Ann Surg; 2005 Mar; 241(3):491-6. PubMed ID: 15729073
[TBL] [Abstract][Full Text] [Related]
33. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
34. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
35. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
36. CEACAM6 is a determinant of pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Benoit E; Ashley SW; Whang EE
Br J Cancer; 2004 Oct; 91(7):1384-90. PubMed ID: 15316565
[TBL] [Abstract][Full Text] [Related]
37. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.
Ling X; Wu W; Aljahdali IAM; Liao J; Santha S; Fountzilas C; Boland PM; Li F
Clin Transl Med; 2022 May; 12(5):e881. PubMed ID: 35604033
[TBL] [Abstract][Full Text] [Related]
38. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.
Knudsen ES; Balaji U; Mannakee B; Vail P; Eslinger C; Moxom C; Mansour J; Witkiewicz AK
Gut; 2018 Mar; 67(3):508-520. PubMed ID: 28073890
[TBL] [Abstract][Full Text] [Related]
40. Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition.
Sharbeen G; McCarroll JA; Akerman A; Kopecky C; Youkhana J; Kokkinos J; Holst J; Boyer C; Erkan M; Goldstein D; Timpson P; Cox TR; Pereira BA; Chitty JL; Fey SK; Najumudeen AK; Campbell AD; Sansom OJ; Ignacio RMC; Naim S; Liu J; Russia N; Lee J; Chou A; Johns A; Gill AJ; Gonzales-Aloy E; Gebski V; Guan YF; Pajic M; Turner N; Apte MV; Davis TP; Morton JP; Haghighi KS; Kasparian J; McLean BJ; Setargew YF; Phillips PA;
Cancer Res; 2021 Jul; 81(13):3461-3479. PubMed ID: 33980655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
